A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer

Cancer Research

Volumn 68, Issue 13, 2008, Pages 5478-5486

  Bonome, Tomas ^a   Levine, Douglas A ^b   Shih, Joanna ^a   Randonovich, Mike ^a   Pise Masison, Cindy A ^a   Bogomolniy, Faina ^b   Ozbun, Laurent ^a   Brady, John ^a   Barrett, J Carl ^a   Boyd, Jeff ^b   Birrer, Michael J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; OVARY CANCER; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; BIOLOGICAL MODEL; CLUSTER ANALYSIS; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MINIMAL RESIDUAL DISEASE; MORTALITY; OVARY TUMOR; PAPILLARY CARCINOMA; SURVIVAL; TREATMENT FAILURE; VALIDATION STUDY;

TUMOR MARKER;

CARCINOMA, PAPILLARY; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASM, RESIDUAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 48549092983     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6595     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994;44:7-26.
3. Boente MP, Hamilton TC, Godwin AK, et al. Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment. Curr Probl Cancer 1996;20:83-137.
4. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-7.
5. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
6. Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005;65: 10602-12.
7. DeRisi JL, Iyer VR, Brown PO. Exploring the metabolic and genetic control of gene expression on a genomic scale. Science 1997;278:680-6.
8. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
9. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005;11:6422-30.
10. Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005;11:3686-96.
11. Lancaster JM, Dressman HK, Whitaker RS, et al. Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 2004;11: 51-9.
12. Spentzos D, Levine DA, Ramoni MF, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004;22:4700-10.
13. Donninger H, Bonome T, Radonovich M, et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 2004;23:8065-77.
14. Wamunyokoli FW, Bonome T, Lee JY, et al. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res 2006;12:690-700.
15. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
16. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
17. Nguyen DV, Rocke DM. Partial least squares proportional hazard regression for application to DNA microarray survival data. Bioinformatics 2002; 18:1625-32.
18. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Series B 1972;34:248-75.
19. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007;99:147-57.
20. Molinaro AM, Simon R, Pfeiffer RM. Prediction error estimation: a comparison of resampling methods. Bioinformatics 2005;21:3301-7.
21. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000;57:1050-93.
22. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000;183:1-9.
23. Hao X, Sun B, Hu L, et al. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 2004;100:1110-22.
24. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
25. Chihara Y, Rakugi H, Ishikawa K, et al. Klotho protein promotes adipocyte differentiation. Endocrinology 2006; 147:3835-42.
26. Chu F, Chou PM, Zheng X, Mirkin BL, Rebbaa A. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 2005;65:10183-7.
27. Ford J, Jiang M, Milner J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 2005;65:10457-63.
28. Hernando E, Nahle Z, Juan G, et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004;430: 797-802.
29. Murakumo Y, Roth T, Ishii H, et al. A human REV7 homolog that interacts with the polymerase ζ catalytic subunit hREV3 and the spindle assembly checkpoint protein hMAD2. J Biol Chem 2000;275:4391-7.
30. Wu F, Lin X, Okuda T, Howell SB. DNA polymerase ζ regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance. Cancer Res 2004;64:8029-35.
31. Della Ragione F, Russo G, Oliva A, et al. 5′-Deoxy-5′- methylthioadenosine phosphorylase and p16INK4 deficiency in multiple tumor cell lines. Oncogene 1995;10: 827-33.
32. Stadler WM, Sherman J, Bohlander SK, et al. Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer. Cancer Res 1994;54:2060-3.
33. Esteve PO, Chin HG, Smallwood A, et al. Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes Dev 2006;20:3089-103.
34. Rice JC, Briggs SD, Ueberheide B, et al. Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Mol Cell 2003;12:1591-8.